{"id":"tenofovir-emtricitabine-lopinavir-ritonavir","safety":{"commonSideEffects":[{"rate":"15-30","effect":"Diarrhea"},{"rate":"10-20","effect":"Nausea"},{"rate":"20-40","effect":"Lipid abnormalities (elevated cholesterol/triglycerides)"},{"rate":"5-15","effect":"Lipodystrophy"},{"rate":"2-5","effect":"Hepatotoxicity"},{"rate":"1-3","effect":"Renal dysfunction (tenofovir-related)"},{"rate":"<1","effect":"Lactic acidosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tenofovir and emtricitabine are nucleoside reverse transcriptase inhibitors (NRTIs) that block HIV reverse transcriptase, preventing viral RNA conversion to DNA. Lopinavir/ritonavir is a protease inhibitor combination where ritonavir boosts lopinavir levels by inhibiting its metabolism, allowing lopinavir to block HIV protease and prevent viral maturation. Together, they suppress HIV replication at multiple stages.","oneSentence":"This combination inhibits HIV reverse transcriptase and protease to suppress viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:11:38.291Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT02302547","phase":"PHASE3","title":"Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2014-12","conditions":"HIV","enrollment":224},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT01234116","phase":"PHASE4","title":"Post-Exposure Prophylaxis in Health Care Workers","status":"COMPLETED","sponsor":"Henry Ford Health System","startDate":"2011-02","conditions":"Human Immunodeficiency Virus","enrollment":16},{"nctId":"NCT07080138","phase":"","title":"Research on the Psychological Status of Patients With HIV-1 Infection","status":"NOT_YET_RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-08-01","conditions":"HIV-1-infection, Anxiety Depression","enrollment":500},{"nctId":"NCT01614405","phase":"NA","title":"Highly Active Antiretroviral Therapy for Patients With Primary Biliary Cirrhosis","status":"TERMINATED","sponsor":"University of Alberta","startDate":"2012-06","conditions":"Primary Biliary Cirrhosis","enrollment":13},{"nctId":"NCT00955968","phase":"PHASE4","title":"IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2010-01-01","conditions":"HIV Infection","enrollment":1653},{"nctId":"NCT00775606","phase":"PHASE4","title":"Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease","status":"TERMINATED","sponsor":"Rush University Medical Center","startDate":"2008-10","conditions":"Acquired Immune Deficiency Syndrome","enrollment":15},{"nctId":"NCT00885664","phase":"PHASE4","title":"Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2005-10","conditions":"HIV Infections","enrollment":60},{"nctId":"NCT01061151","phase":"PHASE3","title":"Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-03-01","conditions":"HIV Infections","enrollment":3747},{"nctId":"NCT02269917","phase":"PHASE3","title":"Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2015-03","conditions":"Human Immunodeficiency Virus Type 1","enrollment":1149},{"nctId":"NCT00074581","phase":"PHASE3","title":"Preventing Sexual Transmission of HIV With Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-02","conditions":"HIV Infections","enrollment":3526},{"nctId":"NCT00039741","phase":"PHASE2, PHASE3","title":"Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-08","conditions":"HIV Infections","enrollment":266},{"nctId":"NCT00099632","phase":"PHASE2","title":"Comparison of Three Anti-HIV Regimens to Prevent Nevirapine Resistance in Women Who Take Nevirapine During Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-03","conditions":"HIV Infections","enrollment":484},{"nctId":"NCT00036452","phase":"PHASE2","title":"A Study to Compare Anti-HIV Drugs Given Twice a Day or Once a Day, With or Without Direct Observation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":402},{"nctId":"NCT00102206","phase":"PHASE2","title":"A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":6},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT01352715","phase":"PHASE3","title":"Study of Options for Second-Line Effective Combination Therapy (SELECT)","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2012-03-13","conditions":"HIV-1 Infection","enrollment":515},{"nctId":"NCT03394196","phase":"NA","title":"RESIST-2: 2nd-line ART for HIV-2 Infection","status":"TERMINATED","sponsor":"University of Washington","startDate":"2018-07-04","conditions":"HIV-2 Infection","enrollment":152},{"nctId":"NCT04311957","phase":"PHASE4","title":"Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed Adults","status":"UNKNOWN","sponsor":"Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic","startDate":"2020-09-01","conditions":"HIV-1-infection, Antiretroviral Therapy","enrollment":386},{"nctId":"NCT02616029","phase":"PHASE3","title":"Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-17","conditions":"HIV-1 Infection","enrollment":66},{"nctId":"NCT00752856","phase":"PHASE2","title":"Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2008-08-26","conditions":"HIV Infections","enrollment":51},{"nctId":"NCT02121795","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-05-06","conditions":"HIV-1 Infection","enrollment":668},{"nctId":"NCT02616783","phase":"PHASE3","title":"Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-22","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT02469246","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-06-29","conditions":"HIV-1 Infection","enrollment":567},{"nctId":"NCT01632891","phase":"PHASE1, PHASE2","title":"Comparing PI-Based to a nNRTI-based ART for Clearance of Plasmodium Falciparum Parasitemia in HIV-Infected","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2014-01-10","conditions":"HIV-1 Infection, Pf Subclinical Parasitemia","enrollment":52},{"nctId":"NCT02150993","phase":"PHASE2, PHASE3","title":"First-Line Treatment for HIV-2","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2016-01-26","conditions":"HIV-2 Infection","enrollment":210},{"nctId":"NCT02116660","phase":"PHASE2","title":"Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-09-03","conditions":"HIV Infections","enrollment":11},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275},{"nctId":"NCT00608569","phase":"NA","title":"Determining the Effects of Observed and Self-Administered Drug Regimens in HIV Infected Adults","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2009-03","conditions":"HIV Infections","enrollment":529},{"nctId":"NCT00089505","phase":"PHASE3","title":"NNRTI vs PI Regimens for HIV Infected Women After They Have Taken Nevirapine to Prevent Mother-To-Child HIV Transmission","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2006-11","conditions":"HIV Infections","enrollment":745},{"nctId":"NCT00090779","phase":"PHASE2","title":"Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV","status":"TERMINATED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2005-01","conditions":"HIV Infections","enrollment":130},{"nctId":"NCT00632970","phase":"PHASE4","title":"Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive Individuals","status":"TERMINATED","sponsor":"George Washington University","startDate":"2008-02","conditions":"HIV Infections","enrollment":6},{"nctId":"NCT00357552","phase":"NA","title":"Safety and Effectiveness of Lopinavir/Ritonavir in Individuals Who Have Failed Prior HIV Therapy","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2008-01","conditions":"HIV Infections","enrollment":123},{"nctId":"NCT00949234","phase":"PHASE2","title":"Interventions for HIV Negative Men and Women Who Have High-risk Suspected Exposure to HIV","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2010-03","conditions":"HIV Prevention, HIV Infections","enrollment":267},{"nctId":"NCT01935830","phase":"EARLY_PHASE1","title":"LAAM-HAART PET Imaging","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2013-08","conditions":"Healthy Volunteers","enrollment":10},{"nctId":"NCT01516970","phase":"PHASE3","title":"Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)","status":"COMPLETED","sponsor":"Janssen-Cilag G.m.b.H","startDate":"2011-11-25","conditions":"Human Immunodeficiency Virus (HIV)","enrollment":312},{"nctId":"NCT01003990","phase":"PHASE3","title":"Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2002-10","conditions":"HIV","enrollment":710},{"nctId":"NCT00928187","phase":"PHASE3","title":"Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé)","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2009-11","conditions":"HIV, HIV Infections","enrollment":454},{"nctId":"NCT02198443","phase":"PHASE4","title":"Comparison of Two Combinations in Antiretroviral Post-Exposure Prophylaxis for HIV-1: Tenofovir/Emtricitabine (Truvada ®) + Lopinavir/Ritonavir (Kaletra ®) vs Tenofovir/Emtricitabine/Cobicistat/Elvitegravir (Stribild ®). Prospective, Randomized, Open.","status":"COMPLETED","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2015-06-06","conditions":"HIV","enrollment":160},{"nctId":"NCT01475838","phase":"PHASE3","title":"Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-11","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":438},{"nctId":"NCT00708162","phase":"PHASE3","title":"Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-07","conditions":"HIV Infection","enrollment":724},{"nctId":"NCT01154673","phase":"PHASE2, PHASE3","title":"Effects of Intensive cART During Acute/Early HIV Infection","status":"COMPLETED","sponsor":"University of Toronto","startDate":"2011-11","conditions":"Acute HIV Infection","enrollment":32},{"nctId":"NCT02157311","phase":"PHASE3","title":"4 Consecutive Days on Treatment Followed by 3 Days Off Treatment, in HIV Patients","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2014-07","conditions":"HIV-1 Infection","enrollment":100},{"nctId":"NCT01585753","phase":"","title":"MARCH Vascular Endothelium Substudy","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2012-06","conditions":"Cardiovascular Disease","enrollment":34},{"nctId":"NCT01637233","phase":"","title":"MARCH Central Nervous System Substudy","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2012-06","conditions":"HIV-1 Infection","enrollment":28},{"nctId":"NCT01637259","phase":"PHASE4","title":"MARCH Renal Substudy","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2012-06","conditions":"Proteinuria, HIV","enrollment":76},{"nctId":"NCT01252940","phase":"PHASE3","title":"Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-11","conditions":"HIV-1 Infection","enrollment":482},{"nctId":"NCT01908660","phase":"","title":"Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life Conditions","status":"COMPLETED","sponsor":"Valme University Hospital","startDate":"2007-01","conditions":"Human Immunodeficiency Virus, Hepatitis B, Chronic, Hepatitis C, Chronic","enrollment":192},{"nctId":"NCT00654147","phase":"PHASE2","title":"Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects","status":"COMPLETED","sponsor":"Margaret A. Fischl, M.D.","startDate":"2008-04","conditions":"HIV Infections","enrollment":44},{"nctId":"NCT01533272","phase":"PHASE4","title":"Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1:FOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC (MARAVI-PEP)","status":"COMPLETED","sponsor":"Hospital Clinic of Barcelona","startDate":"2012-02","conditions":"HIV Infection","enrollment":240},{"nctId":"NCT01576731","phase":"PHASE4","title":"Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir (RAL-PEP)","status":"COMPLETED","sponsor":"Hospital Clinic of Barcelona","startDate":"2012-07","conditions":"HIV Infection","enrollment":240},{"nctId":"NCT01294761","phase":"NA","title":"Comparing Continuing Tenofovir, Emtricitabine (or Lamivudine) Plus Lopinavir and Switching to Raltegravir Plus Darunavir","status":"COMPLETED","sponsor":"National Center for Global Health and Medicine, Japan","startDate":"2011-02","conditions":"HIV Infections","enrollment":59},{"nctId":"NCT01583439","phase":"NA","title":"The Mochudi Prevention Project ART Protocol","status":"TERMINATED","sponsor":"Harvard School of Public Health (HSPH)","startDate":"2012-09","conditions":"HIV Infections","enrollment":11},{"nctId":"NCT02203461","phase":"PHASE1","title":"Changes in Insulin Resistance in Healthy Volunteers on STRIBILD® Medication","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2014-07","conditions":"Insulin Resistance","enrollment":30},{"nctId":"NCT00055120","phase":"PHASE4","title":"When to Start Anti-HIV Drugs in Patients With Opportunistic Infections","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-03","conditions":"HIV Infections, AIDS-Related Opportunistic Infections","enrollment":283},{"nctId":"NCT00978237","phase":"PHASE4","title":"Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients","status":"COMPLETED","sponsor":"Juan A. Arnaiz","startDate":"2009-10","conditions":"HIV Infections, Lipoatrophy","enrollment":20},{"nctId":"NCT00444379","phase":"PHASE4","title":"Anti-Retrovirals for Kaposi's Sarcoma","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2007-04","conditions":"Kaposi's Sarcoma, HIV Infections","enrollment":224},{"nctId":"NCT00946595","phase":"PHASE2, PHASE3","title":"Evaluation of a Lopinavir/Ritonavir Monotherapy vs a Triple Therapy as Maintenance Regimens in HIV-1 Infected Patients","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2009-11","conditions":"HIV Infections","enrollment":420},{"nctId":"NCT00624195","phase":"PHASE2, PHASE3","title":"Clinical Trial of CNS-targeted HAART (CIT2)","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2007-03","conditions":"HIV Infections","enrollment":59},{"nctId":"NCT02097381","phase":"NA","title":"Study of Recovery of Intestinal CD4+ and Th17 T Cells in HIV-infected Individuals on Short-term Antiretroviral Therapy","status":"UNKNOWN","sponsor":"University of Roma La Sapienza","startDate":"2010-04","conditions":"HIV Infection","enrollment":10},{"nctId":"NCT01772940","phase":"PHASE4","title":"Nevirapine vs Ritonavir-boosted Lopinavir in ART Naive HIV-infected Adults in a Resource Limited Setting","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Saint Pierre","startDate":"2008-12","conditions":"HIV-1 Infection","enrollment":425},{"nctId":"NCT00302822","phase":"PHASE3","title":"Intensification With Enfuvirtide in Naive HIV-infected Patients (ANRS130)","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2006-04","conditions":"HIV Infections, AIDS","enrollment":195},{"nctId":"NCT00759070","phase":"PHASE4","title":"Effects of 2 Initial Standard Antiretroviral Combinations Therapies on Lipid Metabolism","status":"UNKNOWN","sponsor":"Juan A. Arnaiz","startDate":"2008-09","conditions":"HIV Infections","enrollment":50},{"nctId":"NCT00532168","phase":"PHASE4","title":"Once-daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/Mcl","status":"COMPLETED","sponsor":"Juan A. Arnaiz","startDate":"2007-09","conditions":"HIV Infections","enrollment":108},{"nctId":"NCT00414518","phase":"NA","title":"Safety and Effectiveness of Short-Term Anti-HIV Drug Therapy for Recent HIV-1 Infection","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2007-01","conditions":"HIV Infections","enrollment":16},{"nctId":"NCT01159743","phase":"","title":"A Comparison of Body Fat Distribution in HIV-1 Infected Patients Receiving, Since the Beginning and for at Least Two Years, an Antiretroviral Therapy Based on Efavirenz or Lopinavir/Ritonavir Combined With Tenofovir + Emtricitabine or Lamivudine","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-07","conditions":"HIV Infection","enrollment":346},{"nctId":"NCT01255371","phase":"PHASE3","title":"A Multicentre Trial of Second-line Antiretroviral Treatment Strategies in African Adults Using Atazanavir or Lopinavir/Ritonavir","status":"WITHDRAWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2012-03","conditions":"HIV","enrollment":""},{"nctId":"NCT00666055","phase":"","title":"Sex, Aging and Antiretroviral Pharmacokinetics","status":"COMPLETED","sponsor":"Kristine Patterson, MD","startDate":"2008-03","conditions":"HIV Infections","enrollment":11},{"nctId":"NCT00827112","phase":"PHASE2","title":"A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2009-03","conditions":"Human Immunodeficiency Virus-1","enrollment":129},{"nctId":"NCT00573001","phase":"PHASE3","title":"Evaluation of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Africa (ANRS 12115 DAYANA)","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2008-07","conditions":"HIV Infections","enrollment":120},{"nctId":"NCT00936195","phase":"PHASE3","title":"Universal Use of EFV-TDF-FTC and AZT-3TC-LPV/r Combinations for HIV-1 PMTCT in Pregnant and Breastfeeding Women : a Phase 3 Trial","status":"WITHDRAWN","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2010-01","conditions":"HIV Infection, Pregnancy, Breastfeeding","enrollment":""},{"nctId":"NCT00711009","phase":"PHASE3","title":"Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)","status":"COMPLETED","sponsor":"Abbott","startDate":"2008-07","conditions":"Human Immunodeficiency Virus Infection","enrollment":206},{"nctId":"NCT00262522","phase":"PHASE3","title":"Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects","status":"COMPLETED","sponsor":"Abbott","startDate":"2005-11","conditions":"Human Immunodeficiency Virus Infections","enrollment":664},{"nctId":"NCT00772902","phase":"PHASE4","title":"ROCKET II - Randomized Open Label Switch for Cholesterol Elevation on Kivexa + Kaletra Evaluation Trial","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-10","conditions":"HIV-1","enrollment":85},{"nctId":"NCT00105079","phase":"PHASE3","title":"GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-04","conditions":"HIV Infections","enrollment":337},{"nctId":"NCT00272779","phase":"PHASE3","title":"BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2005-11","conditions":"HIV Infections","enrollment":1057},{"nctId":"NCT00244712","phase":"PHASE4","title":"Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIV","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-07","conditions":"HIV Infection","enrollment":688},{"nctId":"NCT00121017","phase":"PHASE2","title":"A Study Exploring an Induction-Maintenance Kaletra-Based Therapy Versus a Sustiva-Based Regimen in Previously Non-Treated, HIV-1/HCV Co-Infected Subjects","status":"WITHDRAWN","sponsor":"Abbott","startDate":"","conditions":"HIV Infection, Hepatitis C","enrollment":200},{"nctId":"NCT00043966","phase":"PHASE3","title":"Study of Lopinavir, Ritonavir, Tenofovir and Emtricitabine in HIV-Infected Antiretroviral Naïve Subjects","status":"COMPLETED","sponsor":"Abbott","startDate":"2002-07","conditions":"HIV Infections","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Tenofovir + emtricitabine + lopinavir/ritonavir","genericName":"Tenofovir + emtricitabine + lopinavir/ritonavir","companyName":"Juan A. Arnaiz","companyId":"juan-a-arnaiz","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination inhibits HIV reverse transcriptase and protease to suppress viral replication. Used for HIV-1 infection.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}